LAKE CITY, Sept. 1, 2021 /PRNewswire/ -- Lipocine
Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company
focused on metabolic and endocrine disorders, today announced that
the Company will present at the H.C. Wainwright 23rd Annual
Global Investment Conference being held virtually September 13-15, 2021.
H.C. Wainwright 23rd Annual Global Investment
Conference September 13-15, 2021
Presentation time: September 13,
2021 starting at 7:00 a.m.
A webcast of Lipocine's presentation will be available
on-demand as of 7:00 am ET, Monday, September 13, 2021,
thorough the H.C. Wainwright conference portal, on Lipocine's
website under "Events & Presentations" in the Investors section
or using the webcast link above. The webcast will be
available on the Lipocine's website for 90 days.
Lipocine Inc. is a
clinical-stage biopharmaceutical company focused on metabolic and
endocrine disorders using its proprietary drug delivery
technologies. Lipocine's clinical development pipeline includes:
TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1107 and LPCN 1154.
TLANDO, a novel oral prodrug of testosterone containing
testosterone undecanoate, has received tentative approval from the
FDA for conditions associated with a deficiency of endogenous
testosterone, also known as hypogonadism, in adult males. LPCN
1144, an oral prodrug of bioidentical testosterone, recently
completed a Phase 2 clinical study demonstrating the potential
utility in the treatment of non-cirrhotic NASH. TLANDO
XR, a novel oral prodrug of testosterone, originated and is being
developed by Lipocine as a next-generation oral testosterone
product with potential for once-daily dosing. In a phase 2 clinical
evaluation when administered as once daily or twice daily TLANDO XR
met the typical primary and secondary end points. LPCN 1148 is an
oral prodrug of bioidentical testosterone targeted for the
treatment of cirrhosis. LPCN 1107 is potentially the first oral
hydroxyprogesterone caproate product candidate indicated for the
prevention of recurrent preterm birth and has been granted orphan
drug designation by the FDA. LPCN 1154 is an oral neuro-steroid
targeted for the treatment of post-partum depression. For
more information, please visit www.lipocine.com.
View original content to download
SOURCE Lipocine Inc.